Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for…
- Trial name
- NCT02669615
- Testing
- Melphalan HCl for injection (propylene glycol free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT04398485
- Testing
- ION251
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Multiple Myeloma
Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)
Bortezomib is an established treatment in multiple myeloma; it is common practice in the UK to administer bortezomib with dexamethasone. This practice is based on data that supports improved response rates with this combination.
- Trial name
- MUKfour (NCT01720875)
- Testing
- Vorinostat Velcade Dexamethasone
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Leeds
Leukemia, Lymphoma, Non-Hodgkin
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Primary Objective: To determine if there is significant toxicity associated with the administration of CD34-TK75 transduced donor lymphocytes after allogeneic BMT for relapsed hematologic malignancies Secondary Objectives: To…
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hodgkin Disease, Myelodysplastic Syndromes
- Trial name
- NCT00871702
- Testing
- CD34-TK75 transduced donor lymphocytes, Sub Study - 18 FHBG PET/CT Scans
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Relapse Multiple Myeloma
Melflufen for Elderly Patients With Relapsed Myeloma
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse. Thirty elderly patients at second or subsequent relapse.
- Trial name
- NCT06682637
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Italy
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Primary Objectives: Study Part 1: Determine the selected dose of AVE1642 administered every 3 weeks based on pharmacokinetic (PK) (Clearance of AVE1642), pharmacodynamic (PD) (insulin-like growth factor 1 [IGF-1] serum level)…
- Trial name
- NCT01233895
- Testing
- AVE1642, Velcade
- Where
- 4 sites in France, Italy
- Volunteers
- 26 people
- Sponsor
- Sanofi
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Hodgkin's Lymphoma, Multiple Myeloma
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate.
- Conditions
- Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT01699581
- Testing
- Nestle Impact Advanced Recovery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Greg Monohan
Myeloma Multiple
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM)…
- Trial name
- MUKfourteen (NCT03191981)
- Testing
- Cyclophosphamide, Lenalidomide, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Sponsor
- University of Leeds
Myeloma, Multiple Myeloma
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
The aim of this research study is to evaluate the safety and tolerability of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
- Conditions
- Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT06518551
- Testing
- Elotuzumab, Iberdomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Omar Nadeem, MD
Multiple Myeloma
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
- Trial name
- REVIVE (NCT06100237)
- Testing
- Teclistamab, Talquetamab, Daratumumab SC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carl Ola Landgren, MD, PhD
Leukemia, Lymphoma
Early Integration of Palliative and Supportive Care in Cellular Therapy
Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Blood Cancer
- Trial name
- PALS_CT (NCT05190653)
- Testing
- Early palliative and supportive care
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- Alberta Health Services, Calgary
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with…
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00006251
- Testing
- total-body irradiation, fludarabine phosphate, cyclosporine
- Where
- 2 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
This study will use the drug daratumumab in patients who did not achieve at least a very good partial response (VGPR) and are already planned to have an Autologous Stem Cell Transplant (ASCT).
- Trial name
- NCT04230031
- Testing
- Daratumumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
- Trial name
- NCT02412228
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- John L. Reagan
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back.
- Conditions
- Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
- Trial name
- NCT03311828
- Testing
- Daratumumab, Imaging Agent, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Fatigue, Multiple Myeloma
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma.
- Trial name
- NCT01160380
- Testing
- armodafinil
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.